Company research
ANI PHARMACEUTICALS INC
CIK 1023024Updated Sep 24, 2026
SecurityANIP · NASDAQ · equity
Name history
BIOSANTE PHARMACEUTICALS INC · through Jul 18, 2013BEN ABRAHAM TECHNOLOGIES INC · through Dec 23, 1999
ANIP price & chart
Loading TradingView…
NASDAQ:ANIP on TradingView ↗In the news
ANI Pharmaceuticals to Present at September Investor Conferences ↗
Seeking Alpha
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation ↗
ANI projects $1.08B-$1.14B 2026 revenue as it revises Cortrophin to $520M-$540M amid gout sales force expansion ↗
Recent filings
144 filing
144 filing
4 filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,440,377,000Source | 1,283,697,000Source | 904,422,000Source | 760,087,000Source |
| Property, Plant and Equipment, NetUSD | 62,476,000Source | 56,863,000Source | 44,593,000Source | 43,246,000Source |
| GoodwillUSD | 62,480,000Source | 59,990,000Source | 28,221,000Source | 28,221,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 479,526,000Source | 541,834,000Source | 209,009,000Source | 251,635,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 285,585,000Source | 144,861,000Source | 221,121,000Source | 48,228,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 281,082,000Source | 221,726,000Source | 162,079,000Source | 165,438,000Source |
| Inventory, NetUSD | 143,067,000Source | 136,782,000Source | 111,196,000Source | 105,355,000Source |
| Assets, CurrentUSD | 753,117,000Source | 527,684,000Source | 519,816,000Source | 344,261,000Source |
| Other Assets, NoncurrentUSD | 13,706,000Source | 12,220,000Source | 12,072,000Source | 11,361,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 899,653,000Source | 855,167,000Source | 446,823,000Source | 421,547,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 596,036,000Source | 519,653,000Source | 514,103,000Source | 403,901,000Source |
| Retained Earnings (Accumulated Deficit)USD | -23,099,000Source | -100,279,000Source | -80,132,000Source | -97,286,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,033,000Source | 5,344,000Source | 8,857,000Source | 12,168,000Source |
| Stockholders' Equity Attributable to ParentUSD | 540,724,000Source | 403,680,000Source | 432,749,000Source | 313,690,000Source |
| Liabilities and EquityUSD | 1,440,377,000Source | 1,283,697,000Source | 904,422,000Source | 760,087,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 278,112,000Source | 193,680,000Source | 145,477,000Source | 99,439,000Source |
| Operating Lease, Liability, CurrentUSD | 1,923,000Source | 1,799,000Source | 1,561,000Source | 684,000Source |
| Accounts Payable, CurrentUSD | 62,583,000Source | 45,656,000Source | 36,683,000Source | 29,305,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,173,000Source | 4,393,000Source | 4,111,000Source | 1,381,000Source |
| Other Liabilities, NoncurrentUSD | 12,164,000Source | 5,781,000Source | 4,809,000Source | 1,381,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 16,803,000Source | 13,735,000Source | 5,606,000Source | 5,394,000Source |
| Long-term Debt, Current MaturitiesUSD | 17,268,000Source | 9,172,000Source | 850,000Source | 850,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 291,840,000Source | 309,108,000Source | 284,819,000Source | 285,669,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,929,000Source | 29,344,000Source | 20,652,000Source | 14,599,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 58,530,000Source | 21,087,000Source | -3,359,000Source | 36,912,000Source |
| Increase (Decrease) in InventoriesUSD | 5,961,000Source | 21,287,000Source | 5,841,000Source | 23,626,000Source |
| Increase (Decrease) in Accounts PayableUSD | 15,156,000Source | 479,000Source | 7,552,000Source | 5,038,000Source |
| Deferred Income Tax Expense (Benefit)USD | 11,787,000Source | -22,999,000Source | -11,576,000Source | -15,232,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 185,225,000Source | 64,017,000Source | 118,959,000Source | -31,203,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 0Source | 33,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -34,321,000Source | -404,719,000Source | -18,511,000Source | -15,738,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,835,000Source | 16,236,000Source | 8,868,000Source | 8,876,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 12,209,000Source | 10,959,000Source | 4,987,000Source | 1,959,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -9,944,000Source | 264,945,000Source | 67,439,000Source | -5,126,000Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 140,727,000Source | -76,227,000Source | 167,887,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 285,621,000Source | 144,894,000Source | 221,121,000Source | 53,234,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 26,929,000Source | 24,379,000Source | 31,431,000Source | 21,477,000Source |
| Income Taxes Paid, NetUSD | 17,674,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -233,000Source | -470,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 14,300,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 2,364,000Source | 2,363,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,356,000Source | 642,000Source | 3,922,000Source | 3,961,000Source |
| Amortization of Intangible AssetsUSD | 82,500,000Source | 60,300,000Source | 52,300,000Source | 49,500,000Source |
| DepreciationUSD | 8,900,000Source | 7,400,000Source | 7,500,000Source | 7,400,000Source |
| Other Depreciation and AmortizationUSD | 91,417,000Source | 67,731,000Source | 59,791,000Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 2,824,000Source | 6,307,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | -382,000Source | — | — | — |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | 0Source | 0Source | 750,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | -382,000Source | 5,347,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 5,347,000Source | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 0Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -7,468,000Source | 0Source | — |
| GoodwillUSD | 62,480,000Source | 59,990,000Source | 28,221,000Source | 28,221,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 800,000Source | 3,600,000Source | 0Source | 112,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 4,000,000Source | — | — |
| Income Tax Expense (Benefit)USD | 17,454,000Source | -3,690,000Source | 1,093,000Source | -14,769,000Source |
| Net Income (Loss) Attributable to ParentUSD | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 77,180,000Source | -20,147,000Source | 17,154,000Source | -49,521,000Source |
| Other Interest and Dividend IncomeUSD | 4,874,000Source | 6,266,000Source | — | — |
| Other Nonoperating Income (Expense)USD | 1,934,000Source | -4,033,000Source | -159,000Source | 670,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 0Source | 80,555,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 13,604,000Source | 6,488,000Source | 8,996,000Source | 1,458,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 883,366,000Source | 614,376,000Source | 486,816,000Source | 316,385,000Source |
| Selling, General and Administrative ExpenseUSD | 317,745,000Source | 249,636,000Source | 161,697,000Source | 124,044,000Source |
| Operating Income (Loss)USD | 111,093,000Source | 584,000Source | 46,971,000Source | -35,283,000Source |
| Other Nonoperating Income (Expense)USD | 1,934,000Source | -4,033,000Source | -159,000Source | 670,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 95,791,000Source | -22,212,000Source | 19,872,000Source | -62,665,000Source |
| Income Tax Expense (Benefit)USD | 17,454,000Source | -3,690,000Source | 1,093,000Source | -14,769,000Source |
| Net Income (Loss) Attributable to ParentUSD | 78,337,000Source | -18,522,000Source | 18,779,000Source | -47,896,000Source |
| Earnings Per Share, BasicUSD per share | 3.5Source | -1.04Source | 0.86Source | -3.05Source |
| Earnings Per Share, DilutedUSD per share | 3.32Source | -1.04Source | 0.85Source | -3.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 20,053,000Source | 19,318,000Source | 18,001,000Source | 16,260,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 21,228,000Source | 19,318,000Source | 18,194,000Source | 16,260,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 82,500,000Source | 60,300,000Source | 52,300,000Source | 49,500,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | 341,310,000Source | 250,210,000Source | 181,513,000Source | 138,785,000Source |
| Costs and ExpensesUSD | 772,273,000Source | 613,792,000Source | 439,845,000Source | 351,668,000Source |
| Current Income Tax Expense (Benefit)USD | 2,693,000Source | 17,821,000Source | 12,677,000Source | 467,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 91,417,000Source | 67,731,000Source | 59,791,000Source | 56,972,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | 0Source | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 103,588,000Source | -24,618,000Source | — | — |
| Interest Expense, DebtUSD | 32,562,000Source | 33,628,000Source | 32,469,000Source | 28,418,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -20,060,000Source | -17,602,000Source | -26,940,000Source | -28,052,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 77,180,000Source | -20,147,000Source | 17,154,000Source | -49,521,000Source |
| Other Interest and Dividend IncomeUSD | 4,874,000Source | 6,266,000Source | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | 1,157,000Source | 1,625,000Source | 1,625,000Source | 1,625,000Source |
| Research and Development ExpenseUSD | 51,664,000Source | 44,581,000Source | 34,286,000Source | 22,318,000Source |
| Restructuring and Related Cost, Incurred CostUSD | 0Source | 0Source | 1,132,000Source | 5,679,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | 6,963,000Source | 0Source | 1,679,000Source | — |